Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Economic Value Added (EVA)

Microsoft Excel

EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Boston Scientific Corp., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data reveals notable trends in key profitability and capital metrics over the five-year period examined.

Net Operating Profit After Taxes (NOPAT)
The NOPAT experienced considerable fluctuation, with a high of 1711 million US dollars in 2018, followed by a significant decline to 829 million in 2019 and a further sharp decrease to 153 million in 2020. An improvement occurred in 2021, increasing to 1270 million, though this was followed by a slight decline to 1099 million in 2022. Overall, the NOPAT demonstrates volatility with a notable recovery post-2020 but not reaching initial levels.
Cost of Capital
The cost of capital remained relatively stable throughout the period, ranging between 11.08% and 11.75%. It slightly decreased from 11.75% in 2018 to a low of 11.08% in 2020, before rising moderately to 11.59% in 2022. This stability suggests consistent expectations of return requirements from investors during these years.
Invested Capital
Invested capital showed a steady and continuous increase each year, starting at 16,047 million US dollars in 2018 and growing to 22,868 million by the end of 2022. This upward trend indicates ongoing investments or accumulation of capital assets over the period without significant reductions.
Economic Profit
Economic profit was negative in all years, indicating that returns on invested capital did not exceed the cost of capital. The deficit deepened significantly from -175 million in 2018 to -2180 million in 2020. It improved somewhat in 2021 to -1227 million but worsened again to -1551 million in 2022. Despite the growth in invested capital and partial recovery in NOPAT, economic profit remained negative, reflecting ongoing challenges in generating value above the cost of capital.

In summary, the patterns suggest that although the company increased its invested capital consistently, the operational profitability was unstable and economic profit consistently negative, highlighting a persistent struggle to cover the cost of capital. The partial recovery in NOPAT after 2020 did not translate into positive economic profit, emphasizing areas for potential strategic reassessment.


Net Operating Profit after Taxes (NOPAT)

Boston Scientific Corp., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income (loss)
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for credit losses2
Increase (decrease) in deferred revenue3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for credit losses.

3 Addition of increase (decrease) in deferred revenue.

4 Addition of increase (decrease) in equity equivalents to net income (loss).

5 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net income (loss).

8 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Income (Loss)
The net income demonstrates significant volatility over the analyzed periods. It increased markedly from US$1,671 million in 2018 to a peak of US$4,700 million in 2019. However, the year 2020 saw a sharp reversal, with net income turning into a loss of US$82 million. Following this dip, net income recovered to US$1,041 million in 2021 but declined again to US$698 million in 2022. Overall, the trend indicates substantial fluctuations, with the highest profitability recorded in 2019 and a noticeable setback in 2020, followed by a partial recovery and a subsequent decline.
Net Operating Profit After Taxes (NOPAT)
The NOPAT figures display a different pattern compared to net income. Beginning at US$1,711 million in 2018, NOPAT fell steadily to US$829 million in 2019 and then to a low of US$153 million in 2020. However, it experienced a strong recovery in the subsequent two years, rising to US$1,270 million in 2021 and slightly decreasing to US$1,099 million in 2022. This implies that while operational profitability was significantly impacted during 2019 and 2020, there was a notable operational improvement in 2021 and 2022, albeit not reaching the levels seen in 2018.
Comparative Insights
The considerable divergence between net income and NOPAT in 2019, where net income peaked but NOPAT decreased, may suggest the influence of non-operating factors such as gains, losses, or tax effects that boosted net income independently from operational performance. The loss in net income in 2020 contrasted with a very low but positive NOPAT indicates operational struggles compounded by additional factors impacting overall profitability negatively. The recovery trend in both metrics in 2021 highlights an improvement phase, although 2022 figures show some erosion in profitability relative to 2021. The continued volatility points to potential underlying operational and external challenges affecting the company’s financial outcomes across the five-year period.

Cash Operating Taxes

Boston Scientific Corp., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Income tax expense (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Income Tax Expense (Benefit)
The income tax expense exhibited significant fluctuations over the five-year period. In 2018 and 2019, the company recorded substantial tax benefits of -$249 million and -$4,013 million, respectively. However, the trend reversed in 2020, with a slight positive tax expense of $2 million, followed by a gradual increase to $36 million in 2021 and $443 million in 2022. This shift from large tax benefits to increasing tax expenses suggests a considerable change in tax-related factors affecting the company, possibly reflecting changes in profitability, tax regulations, or deferred tax assets and liabilities.
Cash Operating Taxes
Cash operating taxes showed a consistent upward trend throughout the period analyzed. Starting with a negative value of -$33 million in 2018, cash taxes rose to $377 million in 2019, before experiencing a slight decrease to $165 million in 2020. From 2020 onwards, cash taxes increased steadily to $252 million in 2021 and further to $552 million in 2022. This progression indicates growing cash tax outflows, which may correlate with increasing taxable income, changes in tax strategies, or adjustments in tax payment timings.

Invested Capital

Boston Scientific Corp., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current debt obligations
Long-term debt
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Allowance for credit losses3
Deferred revenue4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Adjusted stockholders’ equity
Capital in progress7
Invested capital

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of deferred revenue.

5 Addition of equity equivalents to stockholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of capital in progress.


Total reported debt & leases
The total reported debt and leases experienced a significant increase from 7,364 million USD in 2018 to 10,351 million USD in 2019. Following this peak, the figure showed a gradual decline over the next three years, decreasing to 9,614 million USD in 2020, 9,525 million USD in 2021, and further to 9,343 million USD by the end of 2022. This pattern indicates a notable rise in leverage in 2019 followed by a steady reduction in debt levels thereafter.
Stockholders’ equity
Stockholders’ equity demonstrated a consistent and substantial upward trend throughout the period. Starting at 8,726 million USD in 2018, equity rose sharply to 13,877 million USD in 2019, and continued to grow annually, reaching 15,326 million USD in 2020, 16,622 million USD in 2021, and 17,573 million USD in 2022. This steady increase reflects a strengthening equity base over the five-year span.
Invested capital
Invested capital showed a pattern of continuous growth, rising from 16,047 million USD in 2018 to 20,389 million USD in 2019. Growth continued but at a slower pace in subsequent years, reaching 21,053 million USD in 2020, 22,038 million USD in 2021, and 22,868 million USD in 2022. The data suggests a deliberate increase in capital investment over time, with the most notable expansion occurring between 2018 and 2019.

Cost of Capital

Boston Scientific Corp., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share ÷ = × =
Outstanding debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Outstanding debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share ÷ = × =
Outstanding debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Outstanding debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share ÷ = × =
Outstanding debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Outstanding debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share ÷ = × =
Outstanding debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in millions

2 Equity. See details »

3 Outstanding debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share ÷ = × =
Outstanding debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in millions

2 Equity. See details »

3 Outstanding debt obligations. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Boston Scientific Corp., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial analysis reveals notable trends across the reported periods.

Economic Profit
The economic profit demonstrates consistent negative values throughout all years, indicating ongoing economic losses. The loss significantly deepened from -175 million US dollars in 2018 to -2,180 million US dollars in 2020. Subsequently, the economic loss decreased in 2021 to -1,227 million US dollars but then increased again in 2022 to -1,551 million US dollars. This pattern suggests fluctuating challenges in generating economic returns beyond the cost of capital.
Invested Capital
There is a clear upward trend in invested capital from 16,047 million US dollars in 2018 to 22,868 million US dollars in 2022. This represents a growth of approximately 42% over the five-year period, indicating continuous investment and expansion in assets employed. The steady increase in invested capital might be linked to growth strategies or capital expenditures aimed at long-term development despite the negative economic profit.
Economic Spread Ratio
The economic spread ratio remains negative for all periods, reflecting that the returns on invested capital are consistently below the cost of capital. The ratio deteriorated from -1.09% in 2018 to a low of -10.36% in 2020, mirroring the period of highest economic losses. Although there was some improvement in 2021 to -5.57%, it worsened again to -6.78% in 2022. This indicator signals ongoing difficulties in achieving satisfactory profitability relative to capital costs.

Overall, the data highlight persistent negative economic profitability despite increasing investments over the years. The company faces challenges in generating sufficient returns above its cost of capital, as evidenced by the negative and volatile economic spread ratio and economic profit. The upward trend in invested capital indicates ongoing commitment to growth or capacity-building, which may affect short-term profitability but could reflect strategic initiatives aimed at future performance improvements.


Economic Profit Margin

Boston Scientific Corp., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Economic profit1
 
Net sales
Add: Increase (decrease) in deferred revenue
Adjusted net sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net sales
= 100 × ÷ =

3 Click competitor name to see calculations.


Economic Profit
The economic profit showed a significant negative trajectory from 2018 through 2020, dropping sharply from -175 million US$ to -2180 million US$. In 2021, there was an improvement with economic profit rising to -1227 million US$, although it remained substantially negative. In 2022, the economic profit again declined to -1551 million US$, indicating ongoing challenges in generating positive economic value.
Adjusted Net Sales
Adjusted net sales exhibited overall growth over the five-year period. The value increased from 9823 million US$ in 2018 to 10762 million US$ in 2019. There was a slight decline to 9908 million US$ in 2020, but sales rebounded strongly in subsequent years, rising to 11977 million US$ in 2021 and reaching 12707 million US$ in 2022. This suggests resilient revenue growth with some fluctuation, particularly in 2020.
Economic Profit Margin
The economic profit margin remained negative throughout the period, reflecting sustained economic losses relative to sales. It worsened drastically from -1.78% in 2018 to -22% in 2020, indicating increased inefficiencies or cost pressures relative to revenue. There was a partial recovery in 2021 to -10.25%, followed by a decline to -12.21% in 2022. Overall, the margin indicates persistent economic underperformance despite growth in net sales.
Summary
While adjusted net sales generally trended upward, indicating strengthening top-line performance, economic profit and economic profit margin remained substantially negative, showing ongoing economic losses. The volatility and improvement in economic profit after 2020 suggest some operational or market factors contributed to reduced losses temporarily. Nonetheless, the negative margins highlight challenges in converting increased sales into economic profitability. Strategic focus on cost management or efficiency improvements may be necessary to achieve positive economic profit in the future.